Immune Modulation Articles & Analysis
21 news found
Responding to the surging global demand for specialized bioactive ingredients, the chemical and material supplier Alfa Chemistry has significantly expanded its catalogue of high-purity hydrolyzed protein peptides. The company now prominently features a diverse range, including sought-after marine-sourced peptides like Fish Collagen Peptide, Marine Fish Oligopeptide, Oyster Peptide, and Sea ...
Creative Biostructure, a leading provider of structural biology services and products, is pleased to announce the expansion of its exosome product line to include a broader range of exosomes isolated from various stem cell lines. This strategic enhancement aims to support and accelerate research in regenerative medicine, drug delivery, and related fields by providing high-quality, stem ...
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Creative BioMart, a renowned provider of innovative life science research solutions, proudly announces its extensive selection of lectins catering to a broad range of research endeavors. Lectins, a class of carbohydrate-binding proteins, hold immense significance in the scientific realm due to their diverse biological functions, encompassing cell adhesion, signal transduction, and immune ...
Creative Enzymes, a prominent player in the biotechnology sector, proudly introduces an innovative line-up of exceptional extracts, tailored to meet a wide spectrum of application needs. From plant extracts and animal extracts to mushroom extracts and vegetable powders, etc., this new collection promises to redefine the utilization of natural ingredients across industries. In a dynamic world ...
Creative Enzymes, a leading provider of innovative enzymes and probiotic solutions, is proud to introduce a range of Lactobacillus strains with enhanced benefits that are designed to revolutionize the way we approach gut health. This high-quality probiotic powder not only offers a wide range of health benefits but also opens up new opportunities for the food and pharmaceutical industries. In ...
MiLaboratories, the global leader in immunome profiling software development, today announced the release of a new version of its flagship product, MiXCR 4.0. MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, ...
BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM ...
JBI-802 is a first-in-class, orally administered, dual equipotent inhibitor of LSD1 & HDAC6 JBI-802 demonstrated synergistic anti-tumor activity in animal models Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the dosing of the first patient in a ...
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert ...
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation ...
GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer ...
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single ...
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced the results from two clinical studies using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual MDS patients were featured in two poster presentations at the 63rd American Society of ...
Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million. The funding will be used to develop a rapid diagnostic that will identify immune subtypes ...
First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven ...
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners. Please contact us for a personal meeting within the partnering system or outside it. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in ...
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) . We look forward meeting potential investors and licensing partners. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome ...
We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV). “During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original ...
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), had successfully completed two Phase I/IIa clinical trials in glioblastoma and pancreatic cancer, respectively. The new data show that ...